Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
This phase I clinical trial studies the safety and best dose of selumetinib and cixutumumab
in treating patients with advanced solid malignancies. Selumetinib may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies,
such as cixutumumab, can block tumor growth in different ways. Some block the ability of
tumor to grow and spread. Others find tumor cells and help kill them or carry
[cancer/tumor]-killing substances to them.